Tailor-made HIV/AIDS treatment closer to reality

Nov 25, 2009

An innovative treatment for HIV patients developed by McGill University Health Centre researchers has passed its first clinical trial with flying colours. The new approach is an immunotherapy customized for each individual patient, and was developed by Dr. J-P. Routy from the Research Institute of the MUHC in collaboration with Dr. R. Sékaly from the Université de Montréal. "This is a vaccine made for the individual patient - an "haute couture" therapy, instead of an off-the-rack treatment" said Dr Routy.

By "priming" the immune system, as with a vaccine, to fight the specific strain of /AIDS infecting a given patient, the scientists believe they have developed a therapy that shows immense promise and could be an even more effective weapon against the virus than the anti-retroviral cocktails currently in use. The results of the first-stage clinical trials, which tested the therapy in conjunction with anti-retroviral drugs, were published recently in Clinical Immunology. Phase 2 of the clinical trial, which is nearly complete, is testing the therapy's efficacy on its own at 8 different sites in Canada.

The new therapy uses dendritic cells which are removed from each HIV-infected patient and subsequently multiplied in-vitro. Dendritic cells present material from invading viruses on their surface, allowing the rest of the immune system to identify and attack the invaders. "They are the "grand conductors" of the immune response," explains Dr Routy. "With them, you push the immune system, in all its functions, at the same time." In the current trial, dendritic cells were exposed to a sample of HIV RNA (ribonucleic acid) specific to the patient involved. This exposure encouraged the cells to develop defences specific to that viral strain. The modified cells - called AGS-004 - were then injected back into the patients.

Not only were there few reported side-effects from the AGS-004, but the researchers also measured increased levels of CD8-lymphocytes in the patients - the "attack" cells of the human immune system that the treatment is intended to mobilize, thus confirming that the intervention was targeted and controlled.

By boosting the in this way, Routy hopes to develop an HIV/AIDS treatment that will require fewer injections and less long-term toxicity for than antriretrovirals.

Source: McGill University Health Centre (news : web)

Explore further: Lift U.S. ban on blood donations by gay men, experts say

add to favorites email to friend print save as pdf

Related Stories

Personalized immunotherapy to fight HIV/AIDS

Aug 15, 2008

For a long time, the main obstacle to creating an AIDS vaccine has been the high genetic variability of the HIV virus. Dr. Jean-Pierre Routy and his team from the Research Institute of the McGill University Health Centre ...

Genetic cause of innate resistance to HIV/AIDS

Jul 16, 2008

Some people may be naturally resistant to infection with HIV, the virus that causes AIDS. The results of a study conducted by Dr. Nicole Bernard of the Research Institute of the McGill University Health Centre (MUHC) bring ...

Novel method to create personalized immunotherapy treatments

Aug 05, 2008

Argos Therapeutics and Université de Montréal today announced the presentation of new information on Argos' process for developing dendritic cell-based immunotherapies for HIV. Results from the study demonstrate that loading ...

Clinical trial evaluating brain cancer vaccine is underway

Oct 19, 2007

A clinical trial evaluating a brain cancer vaccine in patients with newly diagnosed brain cancer has begun at NYU Medical Center. The study will evaluate the addition of the vaccine following standard therapy with surgery ...

Recommended for you

How we got ahead in HIV control

Jul 25, 2014

When AIDS first emerged in the early 1980s, HIV infection was a death sentence. But a global effort has ensured this is no longer the case for a growing number of people.

User comments : 0